

## **Executive Summary**

### **Migraine Pathway Transformation: Collaborative Working Project**

#### **Organisations Involved:**

AbbVie & Health Innovation Manchester (HInM) hosted by Manchester University NHS Foundation Trust (MFT)

#### **Project Summary**

AbbVie and HInM are working collaboratively to understand, reimagine and transform care and outcomes for migraine patients across the Greater Manchester (GM) Healthcare System.

The objectives are to identify and address the current challenges within the migraine pathway across GM, with a focus on supporting earlier diagnosis, enhancing management, and improving patient access to appropriate care whilst driving system efficiencies throughout the migraine pathway.

The project will be delivered across 3 distinct phases:

Phase 1 – Understand the current standard of care for migraine patients in Greater Manchester.

Phase 2 – Reimagine migraine services and pathways to support earlier diagnosis, as well as improve patient experience and outcomes.

Phase 3 – Work collaboratively to implement and evaluate agreed solutions and service optimization recommendations

#### **Expected Benefits**

##### **Anticipated benefits for patients:**

- Improved migraine management with earlier diagnosis, improved care pathways, and enhanced support for self-management.
- Better overall quality of life for migraine patients & improving the patient care experience.
- Reduced burden of migraine on sufferers due to proactive, patient-centered care.
- Faster and improved access to appropriate, guideline-recommended treatments for patients, including NICE-approved therapies.

##### **Anticipated Benefits for the NHS**

- Reduced pressure on secondary care by enabling earlier intervention and empowering primary care.

- Improved system efficiency through standardised pathways and reduced unwarranted variation.
- Enhanced workforce experience with clearer roles and reduced administrative burden.
- Economic benefits from reduced absenteeism and improved productivity, supporting NHS sustainability goals.

#### **Anticipated Benefits for AbbVie**

- Improved understanding of the current migraine pathway across the Greater Manchester system and the proposed solutions to address this.
- Opportunity to support the development and delivery of more efficient care pathways.
- Enhanced reputation and relationships with NHS partners through successful delivery of scalable, patient-focused solutions.

**Start Date:** January 2026. The project is anticipated to last 24 months

**Contact:** AbbVie Ltd AbbVie House Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

**Email:** [centralisationteam@abbvie.com](mailto:centralisationteam@abbvie.com)

**This executive summary is published on:** [www.abbvie.co.uk](http://www.abbvie.co.uk)